Welcome to the ARESTIN Student Access Program, 

On this page, you’ll find downloadable education materials to use in your classroom

The Faculty Guide is designed for you to help teach students about treating periodontal disease and how ARESTIN (minocycline HCl) Microspheres, 1 mg can help.

With hands-on training and quizzes to guide learning, the Faculty Guide gives you all of the resources you'll need to get started with the program.



The ARESTIN Student Access Program is divided into 2 sections and is designed to complement your current periodontal curriculum.

Jump to: ARESTIN 101 | ARESTIN 201 | Certificate of Completion


ARESTIN 101 Curriculum

ARESTIN 101 is an introduction to periodontal disease and treatment that includes ARESTIN + scaling and root planing (SRP). Clinician-patient communication is also highlighted in this section.

  • Classwork focuses on disease state, clinical efficacy, and safety data
  • Laboratory session focuses on proper placement of ARESTIN and communication techniques that can be used to explain periodontal disease and treatment options

In ARESTIN 101, you can expect your students to learn:

  1. The benefits of periodontal treatment that includes ARESTIN + SRP, when indicated
  2. The indication and contraindications for using ARESTIN
  3. How and when ARESTIN can be incorporated into a patient’s treatment plan
  4. The importance of good patient communication

ARESTIN 101 Classroom Materials

ARESTIN 201 Curriculum

ARESTIN 201 deals with the clinical use and application of ARESTIN with an emphasis on case study development.

  • Classwork focuses on treatment planning
  • Clinical session focuses on periodontal patient case development and treatment with ARESTIN

In ARESTIN 201, you can expect your students to learn how to:

  1. Recognize appropriate patients for periodontal treatment that includes ARESTIN + SRP
  2. Prepare a treatment plan for a periodontal patient
  3. Apply diagnostic guidelines in a clinical setting
  4. Demonstrate competency in placing ARESTIN in the clinical setting

ARESTIN 201 Classroom Materials

Certificate of Completion

You can customize this downloadable certificate for all of your students who complete the program.

Download Certificate here

The ARESTIN Student Access Program is sponsored by OraPharma, a division of Bausch Health US, LLC.

Enroll Your School

Once enrolled, learn how you can request samples for clinical use.

Enroll Now

Profile

Name:

Manage Profile

Error:

Help

Questions? Contact us at 1-866-273-7846 or studentaccess@orapharma.com.

The ARESTIN Student Access Program is sponsored by OraPharma, a division of Bausch Health US, LLC.

See More

IMPORTANT SAFETY INFORMATION AND INDICATION

  • ARESTIN® (minocycline HCl) is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
See Less

IMPORTANT SAFETY INFORMATION AND INDICATION

  • ARESTIN® (minocycline HCl) is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

Click here for full Prescribing Information.